6. STOCK COMPENSATION

Stock Incentive Plans

In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Board of Directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is 20. At June 30, 2026, there were 9 shares available for grant under the 2018 Plan.

On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Stock Plan”). A total of 61 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. On April 28, 2026, the Company’s board of directors approved Amendment No. 1 to the 2021 Stock Plan, which was further approved by the shareholders on June 9, 2026, to increase the number of shares of common stock issuable by 600,000. At June 30, 2026, there were 600,025 shares available for grant under the 2021 Plan.

Stock Award Activity

The following is a summary of stock option activity for the six months ended June 30, 2026:

There were no stock options or restricted stock awards granted during the six months ended June 30, 2026.  

Stock-Based Compensation Expense

For the three and six months ended June 30, 2026, and 2025, the Company recorded stock-based compensation expense as follows:

At June 30, 2026, there was no unrecognized compensation expense related to non-vested stock option awards and non-vested restricted stock awards.